Table 1 Surveillance radiologic imaging after oropharynx cancer treatment
From: Surveillance radiologic imaging after treatment of oropharyngeal cancer: a review
Imaging modality | Reference (year) |
|---|---|
Ultrasound | Hwang et al. (2009) [12]; Wierzbicka et al. (2011) [13]: comparison of US versus PET/CT for staging and surveillance of head/neck and thyroid cancer |
MRI | Kangelaris et al. (2010) [14]: MRI for surveillance after chemoradiation treatment of oropharynx cancer |
Vandecaveye et al. (2007) [15]: diffusion-weighted MRI for head/neck cancer after chemoradiation | |
PET | Krabbe et al. (2009) [16]; Kao et al. (2009) [17]; Abgral et al. (2009) [18]; Manikantan et al. (2009) [19]: sensitivity of PET/CT for recurrent head and neck cancer |
Isles et al. (2008) [20]: systematic review of PET for follow-up of head/neck cancer after radiation | |
McDermott et al. (2013) [21]: negative predictive value of PET/CT for head/neck surveillance | |
Zhang et al. (2011) [22]; Koshkareva et al. (2014) [23]: PET/CT for surveillance of HPV+ oropharynx cancer | |
Ho et al. (2013) [25]; Dunsky et al. (2013) [26]; Patel et al. (2013) [27]: lack of survival benefit for routine PET/CT surveillance program | |
Future directions in surveillance imaging | Lee et al. (2014) [28]: PET/MRI for head/neck cancer |
Bogdanov and Mazzanti (2011) [29]; Yankeelov et al. (2011) [30]; Glunde and Bhujwalla (2011) [31]: newer contrast agents and tumor biomarkers for MR imaging | |
Differding et al. (2015) [32]; Servagi-Vernat et al. (2014) [33]: PET imaging biomarkers in head and neck cancer |